title: Survival times for canine intranasal sarcomas treated with radiation therapy: 86 cases (1996-2011).
abstract: Sarcomas comprise approximately one-third of canine intranasal tumors, however few veterinary studies have described survival times of dogs with histologic subtypes of sarcomas separately from other intranasal tumors. One objective of this study was to describe median survival times for dogs treated with radiation therapy for intranasal sarcomas. A second objective was to compare survival times for dogs treated with three radiation therapy protocols: daily-fractionated radiation therapy; Monday, Wednesday, and Friday fractionated radiation therapy; and palliative radiation therapy. Medical records were retrospectively reviewed for dogs that had been treated with radiation therapy for confirmed intranasal sarcoma. A total of 86 dogs met inclusion criteria. Overall median survival time for included dogs was 444 days. Median survival time for dogs with chondrosarcoma (n = 42) was 463 days, fibrosarcoma (n = 12) 379 days, osteosarcoma (n = 6) 624 days, and undifferentiated sarcoma (n = 22) 344 days. Dogs treated with daily-fractionated radiation therapy protocols; Monday, Wednesday and Friday fractionated radiation therapy protocols; and palliative radiation therapy protocols had median survival times of 641, 347, and 305 days, respectively. A significant difference in survival time was found for dogs receiving curative intent radiation therapy vs. palliative radiation therapy (P = 0.032). A significant difference in survival time was also found for dogs receiving daily-fractionated radiation therapy vs. Monday, Wednesday and Friday fractionated radiation therapy (P = 0.0134). Findings from this study support the use of curative intent radiation therapy for dogs with intranasal sarcoma. Future prospective, randomized trials are needed for confirmation of treatment benefits.
authors.affiliation: Department of Clinical Sciences, Auburn University College of Veterinary Medicine, AL, USA. eas0021@auburn.edu
authors.forename: Evan
authors.initials: E
authors.lastname: Sones
authors.forename: Annette
authors.initials: A
authors.lastname: Smith
authors.forename: Stephanie
authors.initials: S
authors.lastname: Schleis
authors.forename: William
authors.initials: W
authors.lastname: Brawner
authors.forename: Gregory
authors.initials: G
authors.lastname: Almond
authors.forename: Kathryn
authors.initials: K
authors.lastname: Taylor
authors.forename: Siobhan
authors.initials: S
authors.lastname: Haney
authors.forename: Jackie
authors.initials: J
authors.lastname: Wypij
authors.forename: Michele
authors.initials: M
authors.lastname: Keyerleber
authors.forename: Jennifer
authors.initials: J
authors.lastname: Arthur
authors.forename: Terrance
authors.initials: T
authors.lastname: Hamilton
authors.forename: Jessica
authors.initials: J
authors.lastname: Lawrence
authors.forename: Tracy
authors.initials: T
authors.lastname: Gieger
authors.forename: Rance
authors.initials: R
authors.lastname: Sellon
authors.forename: Zack
authors.initials: Z
authors.lastname: Wright
mesh_terms: D000818:Animals; D002813:Chondrosarcoma / Q000532:radiotherapy / Q000662:veterinary; D003131:Combined Modality Therapy / Q000662:veterinary; D004283:Dog Diseases / Q000532:radiotherapy*; D004285:Dogs; D019583:Dose Fractionation, Radiation; D004358:Drug Therapy / Q000662:veterinary; D005260:Female; D005354:Fibrosarcoma / Q000532:radiotherapy / Q000662:veterinary; D008297:Male; D009669:Nose Neoplasms / Q000532:radiotherapy / Q000662:veterinary*; D012516:Osteosarcoma / Q000532:radiotherapy / Q000662:veterinary; D011379:Prognosis; D011878:Radiotherapy / Q000662:veterinary; D012189:Retrospective Studies; D012509:Sarcoma / Q000532:radiotherapy / Q000662:veterinary*; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome